The Global Health Drug Discovery Institute (GHDDI) Licenses Scilligence ELN
The Global Health Drug Discovery Institute (GHDDI) has licensed Scilligence Electronic Laboratory Notebook (ELN). Scilligence ELN will help GHDDI to strength collaboration within the organization by digitalizing experimental data. GHDDI researchers are now able to easily search and organize their experiments and associated files.
About The Global Health Drug Discovery Institute (GHDDI)
The Global Health Drug Discovery Institute (GHDDI) identifies and develops innovative approaches to new medicines for diseases most damaging to populations in the developing world. Being the first independent, not-for-profit research institute of its kind in China, GHDDI strives to establish a transformative drug discovery and translational platform with advanced biomedical research and development capabilities – from the bench to the bedside. GHDDI is jointly founded by the Bill and Melinda Gates Foundation, Tsinghua University, and the Beijing Municipal Government, and is closely partnered with the California Institute for Biomedical Research (Calibr) in scientific research.
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.